Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide

Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following a clinical trial that showed response rates in at...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirando, Adam C., Patil, Akash, Rafie, Christine I., Christmas, Brian J., Pandey, Niranjan B., Stearns, Vered, Jaffee, Elizabeth M., Roussos Torres, Evanthia T., Popel, Aleksander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458646/
https://www.ncbi.nlm.nih.gov/pubmed/32923118
http://dx.doi.org/10.1080/2162402X.2020.1760685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458646/
https://www.ncbi.nlm.nih.gov/pubmed/32923118
http://dx.doi.org/10.1080/2162402X.2020.1760685

Ejemplares similares